Breakthrough Reveals Tylenol Blocks Pain at Its Source
A landmark study from the Hebrew University of Jerusalem challenges long-held beliefs about acetaminophen's mode of action, showing that its metabolite, AM404, halts pain signals in peripheral nerves by inhibiting specific sodium channels. This discovery, published in PNAS on 10 June 2025, marks a pivotal shift in pain management science.
Historically, acetaminophen was thought to work primarily in the brain and spinal cord. The new research uncovers a peripheral mechanism: AM404 is generated in pain-sensing nerve endings and blocks voltage-gated sodium channels — specifically NaV1.7 and NaV1.8 — preventing pain signals from ever firing.
The study was led by Professor Alexander Binshtok and Professor Avi Priel, combining expertise from the Faculty of Medicine and School of Pharmacy. Their team demonstrated that AM404 is synthesised locally in nociceptors and directly inhibits sodium currents, significantly reducing pain behaviours in both normal and inflamed rat models.
ADVERTISEMENT
This peripheral action mirrors the effect of local anaesthetics but targets only the nerves responsible for pain perception. As a result, AM404-based interventions could preserve motor and sensory functions, avoiding numbness or weakness commonly associated with traditional local anaesthetics.
Prof. Binshtok stated, 'This is the first time we've shown that AM404 works directly on the nerves outside the brain. It changes our entire understanding of how acetaminophen fights pain'. Prof. Priel added that exploiting AM404's selectivity could lead to safer, more precise analgesics that bypass the side effects of existing medications.
Published on 10 June 2025, the paper titled 'The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels' identifies the compound's mechanism as state-dependent binding to the local anaesthetic site on NaV1.7 and NaV1.8 channels. These findings correct the incomplete understanding of acetaminophen as primarily a central nervous system agent and highlight a dual mechanism involving both central and peripheral pathways.
Other experts in neuroscience are welcoming the breakthrough. Commentary in Medical Xpress noted that this 'ends a longstanding mystery' about how acetaminophen relieves pain. IFL Science emphasises the therapeutic promise: AM404's ability to selectively silence pain neurons could inspire local anaesthetics without typical side effects.
From a pharmacological perspective, this discovery aligns with earlier theories by researchers like Stephen Waxman, who posited that peripheral sodium channels are viable targets for analgesia. NaV1.7 and NaV1.8 are central to pain signalling in peripheral neurons, a fact that has spurred generations of drug discovery efforts.
Beyond academic significance, this insight opens a new paradigm for drug development. AM404's specific action suggests that chemists could design molecules that mimic or enhance its peripheral blocking properties, potentially offering pain relief without impairing motor function or causing dependency.
The clinical implications are substantial. Opioids and traditional local anaesthetics carry risks of addiction, motor impairment, and systemic side effects. AM404-inspired drugs could provide non-addictive, nerve-targeted alternatives with fewer adverse effects, particularly in postoperative and chronic pain management.
Next steps centre on translating these findings into human studies. Researchers must investigate whether AM404 concentrations in human peripheral tissues reach effective levels and evaluate long-term safety, metabolism, and efficacy across diverse patient populations. As Prof. Binshtok and Prof. Priel note, the journey has begun but much work remains to assess clinical potential.
The discovery adds to a growing trend of re-evaluating old medications with modern techniques, uncovering their hidden benefits. It comes one month after Indiana University researchers pointed to acetaminophen's influence on endocannabinoid metabolism — another central mechanism — suggesting that the drug's effects may be multifaceted.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
11-06-2025
- Arabian Post
Breakthrough Reveals Tylenol Blocks Pain at Its Source
A landmark study from the Hebrew University of Jerusalem challenges long-held beliefs about acetaminophen's mode of action, showing that its metabolite, AM404, halts pain signals in peripheral nerves by inhibiting specific sodium channels. This discovery, published in PNAS on 10 June 2025, marks a pivotal shift in pain management science. Historically, acetaminophen was thought to work primarily in the brain and spinal cord. The new research uncovers a peripheral mechanism: AM404 is generated in pain-sensing nerve endings and blocks voltage-gated sodium channels — specifically NaV1.7 and NaV1.8 — preventing pain signals from ever firing. The study was led by Professor Alexander Binshtok and Professor Avi Priel, combining expertise from the Faculty of Medicine and School of Pharmacy. Their team demonstrated that AM404 is synthesised locally in nociceptors and directly inhibits sodium currents, significantly reducing pain behaviours in both normal and inflamed rat models. ADVERTISEMENT This peripheral action mirrors the effect of local anaesthetics but targets only the nerves responsible for pain perception. As a result, AM404-based interventions could preserve motor and sensory functions, avoiding numbness or weakness commonly associated with traditional local anaesthetics. Prof. Binshtok stated, 'This is the first time we've shown that AM404 works directly on the nerves outside the brain. It changes our entire understanding of how acetaminophen fights pain'. Prof. Priel added that exploiting AM404's selectivity could lead to safer, more precise analgesics that bypass the side effects of existing medications. Published on 10 June 2025, the paper titled 'The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels' identifies the compound's mechanism as state-dependent binding to the local anaesthetic site on NaV1.7 and NaV1.8 channels. These findings correct the incomplete understanding of acetaminophen as primarily a central nervous system agent and highlight a dual mechanism involving both central and peripheral pathways. Other experts in neuroscience are welcoming the breakthrough. Commentary in Medical Xpress noted that this 'ends a longstanding mystery' about how acetaminophen relieves pain. IFL Science emphasises the therapeutic promise: AM404's ability to selectively silence pain neurons could inspire local anaesthetics without typical side effects. From a pharmacological perspective, this discovery aligns with earlier theories by researchers like Stephen Waxman, who posited that peripheral sodium channels are viable targets for analgesia. NaV1.7 and NaV1.8 are central to pain signalling in peripheral neurons, a fact that has spurred generations of drug discovery efforts. Beyond academic significance, this insight opens a new paradigm for drug development. AM404's specific action suggests that chemists could design molecules that mimic or enhance its peripheral blocking properties, potentially offering pain relief without impairing motor function or causing dependency. The clinical implications are substantial. Opioids and traditional local anaesthetics carry risks of addiction, motor impairment, and systemic side effects. AM404-inspired drugs could provide non-addictive, nerve-targeted alternatives with fewer adverse effects, particularly in postoperative and chronic pain management. Next steps centre on translating these findings into human studies. Researchers must investigate whether AM404 concentrations in human peripheral tissues reach effective levels and evaluate long-term safety, metabolism, and efficacy across diverse patient populations. As Prof. Binshtok and Prof. Priel note, the journey has begun but much work remains to assess clinical potential. The discovery adds to a growing trend of re-evaluating old medications with modern techniques, uncovering their hidden benefits. It comes one month after Indiana University researchers pointed to acetaminophen's influence on endocannabinoid metabolism — another central mechanism — suggesting that the drug's effects may be multifaceted.
Gulf News
13-02-2025
- Gulf News
Study links DNA traits to risk level for smoking-related cancer
Jerusalem: A team of Israeli researchers has identified how the structure and chemical changes in the DNA influence the risk of developing lung cancer from smoking. The team from the Hebrew University of Jerusalem focused on benzo(a)pyrene, a toxic chemical in cigarette smoke, which binds to DNA when processed by the body, disrupts its normal function, and causes damage to cells, Xinhua news agency reported. The study, published in Nucleic Acids Research, found that the way DNA is organised and chemically altered can affect how smoking damages it, how well the body cells repair the damage, and how many mutations result from it. It discovered that certain regions of DNA, particularly those that are more open and active, are more vulnerable to damage but also better at repairing themselves, and tend to have fewer mutations over time, whereas regions less efficiently repaired may accumulate mutations, increasing the risk of cancer. The study also found that proteins regulating gene activity can sometimes protect DNA from harm, but in other cases, they can make it more vulnerable to damage, the researchers said. The body's ability to repair DNA damage plays a more significant role in determining whether mutations occur, rather than just the amount of damage itself, they added. The study offers new insights into how smoking leads to lung cancer by damaging DNA and causing mutation and could help shape future strategies for cancer prevention and treatment. According to the World Health Organisation (WHO), tobacco use accounts for 25 per cent of all cancer deaths globally and is the primary cause of lung cancer. It remains a public health issue of the utmost importance in the Region, where an estimated 186 million people (or 26 per cent of the adult population) currently use tobacco. Smokers are up to 22 times more likely to develop lung cancer in their lifetime compared to non-smokers. Sign up for the Daily Briefing Get the latest news and updates straight to your inbox
Zawya
24-11-2024
- Zawya
9th edition of SPNS Conference takes off today in Riyadh
Riyadh, Saudi Arabia: The 9th edition of the Saudi Pediatric Neurology Society (SPNS) Conference and Workshops takes off today in Riyadh, Saudi Arabia, the leading event organised by Maarefah Management, and featuring cutting-edge discussions and insights into various pediatric neurology topics. With participation of top healthcare officials, dignitaries, industry leaders, speakers, panellists', analysts and experts. Prof. Fahad Al Bashiri, President SPNS, professor and consultant Pediatric Neurologist at the College of Medicine, King Saud University, will be sharing pivotal insights about the importance of vitamin 'D' in children's health and the recommended dose in children with epilepsy. Prof. Fahad Al Bashiri, said: 'Vitamin D plays a crucial role in maintaining bone health, muscle strength, immune function, and neurotransmission in the central nervous system in healthy children, patients with epilepsy are at high risk of developing vitamin D deficiency due to antiseizure medications (ASMs), leading to impaired bone quality and increased risk of fractures'. 'For children with epilepsy, there is a lack of conclusive evidence to recommend a specific maintenance dose Vitamin 'D'. In trial was approved by the institutional review board at King Saud University, correcting vitamin D deficiency status led to an increased number of seizure-free children, the treatment of 2.6 children with vitamin D deficiency was needed to increase the chances of being seizure-free, Vitamin 'D'treatment for adults with epilepsy lead to a reduction of seizure frequency by 30% in the treatment group compared to the control group, A pilot study in adults showed a significant 40%seizure reduction post-correction of vitD deficiency Hollo'. Added Prof. Fahad Al Bashiri. This year's conference promises an enriching programme featuring cutting-edge discussions and insights into various pediatric neurology topics, including: Neonatal Neurology. Spinal Muscular Atrophy (SMA). Neuro inflammatory Disorders. Neuromuscular Diseases. Brain and Spinal Injuries and Infections. Epilepsy – Brain and Spinal Tumors. Cerebrovascular Disease. Autism. Movement Disorders. Metabolic and Genetic Disorders. Prof. Mohammad Jan, Professor and Consultant of Pediatric Neurology and Clinical Neurophysiology Department of Paediatrics, Faculty of Medicine, King AbdulAziz University, KSA, commented, : Known consequence of primary or metastatic brain tumours, presenting manifestation in 13–24% of children, the only clinical manifestation in 7%, seizure control often aligns with tumour growth can improve with tumour treatment. Brain tumors are the second most common cancer types in children, overall annual incidence 7/100,000 population'. Dr. Raidah Al-Baradie, Consultant Pediatric Neurology/Epilepsy, King Fahd specialist Hospital- Dammam: 'Epilepsy affects 50-70 million people worldwide, and nearly 1 % population will have epilepsy during lifetime, patients have recurrent unprovoked seizures which are clinical manifestation of abnormal neuronal discharges. Increased drugs options have not led to better outcomes, patients endure recurrent seizures before the 'right' drug is found, and there is a need to predict response to specific drugs for individual patients'. 'More than 30 new ASM approved in the past 30 years, No change in overall seizure freedom rate or tolerability, and one third of patients drug resistant, failure of the first drug is the strongest predictor of long term outcome, Choosing ASMs remains largely trial & error for individual patients, Machine learning model may serve as clinical decision support tool in drug selection, and prospective evaluation is needed' Dr. Raidah Al-Baradie, concluded. For more information about The 9th edition of the Saudi Pediatric Neurology Society (SPNS) Conference, please visit:
